

Product Data Sheet

Product Name: PT-2385
Cat. No.: GC32680

Chemical Properties

Cas. No. 1672665-49-4

SMILES N#CC1=CC(F)=CC(OC2=CC=C(S(=O)(C)=O)C3=C2CC(F)(F)[C@H]3O)=C1


Formula $C_{17}H_{12}F_3NO_4S$ M.Wt 383.34

Solubility DMSO : ≥ 50 mg/mL (130.43 mM) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

PT-2385 is a selective HIF-2 α antagonist with a K_i of less than 50 nM.

PT-2385 (PT2385) is a selective antagonist of HIF-2 over HIF-1. PT-2385 is inactive for HIF-1 α [1].

PT-2385 (PT2385) inhibits expression of HIF-2 α regulated genes in a dose dependent manner in vivo. Tumor is regressed with PT-2385 (3 and 10 mg/kg, p.o., b.i.d. dose) in 786-O xenograft. PT-2385 (1,3 and 10 mg/kg) also inhibits tumor-derived VEGFA protein levels. PT-2385 (10 mg/kg)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

treatment reduces proliferation (Ki67) and angiogenesis (CD-31)[1].

[1]. Eli Wallace, Ph.D. PT2385: HIF-2 α Antagonist for the Treatment of VHL Mutant ccRCC. 12th International VHL Medical Symposium April 8, 2016. [2]. Xie C, et al. Activation of intestinal hypoxia-inducible factor 2 α during obesity contributes to hepatic steatosis. Nat Med. 2017 Nov;23(11):1298-1308.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA